Insider · CIK 0001657719

Watson David O.

Reports to the SEC for 1 company · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001657719

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	General Counsel	UDisposition from Tender	−145K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	General Counsel	UDisposition from Tender	−10K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.U Disposition from Tender	General Counsel	UDisposition from Tender	−50.1K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+41.3K sh	—	—	41,250
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−41.3K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+28.5K sh	—	—	28,508
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−28.5K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+28K sh	—	—	27,993
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−28K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+56K sh	—	—	55,986
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−56K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−32.1K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−56K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−11.9K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−6,001 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc.D Disposition to Issuer	General Counsel	DDisposition to Issuer	−7,363 sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−82.5K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−14K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−51K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−38.3K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−45K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−37.7K sh	—	—	0
2026-05-14	APLSApellis Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	General Counsel	DDisposition to Issuer	−34.5K sh	—	—	0
2026-01-28	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+56K sh	—	—	144,517
2026-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−7,832 sh	$21.77	−$170K	88,531
2026-01-20	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−2,475 sh	$19.79	−$49K	96,363
2026-01-13	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,780 sh	$22.19	−$128K	98,838
2026-01-07	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+888 sh	$14.95	+$13.3K	104,618
2026-01-07	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	General Counsel	MExercise/Conversion	−888 sh	—	—	14,000
2025-12-16	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$24.49	−$122K	103,730
2025-11-17	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$20.06	−$100K	108,730
2025-10-16	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$25.22	−$126K	113,730
2025-09-16	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$24.34	−$122K	118,730
2025-09-10	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−20K sh	$26.17	−$523K	50,136
2025-08-18	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$27.80	−$139K	123,730
2025-07-16	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$19.55	−$97.8K	128,730
2025-06-16	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$18.77	−$93.9K	133,730
2025-06-09	APLSApellis Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	General Counsel	AAward	+82.5K sh	$19.39	+$1.6M	82,500
2025-03-05	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,569 sh	$25.10	−$140K	138,730
2025-03-04	APLSApellis Pharmaceuticals, Inc.G Gift	General Counsel	GGift	−6,667 sh	—	—	0
2025-03-04	APLSApellis Pharmaceuticals, Inc.G Gift	General Counsel	GGift	+6,667 sh	—	—	10,000
2025-01-29	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−695 sh	$29.52	−$20.5K	144,299
2025-01-22	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−3,323 sh	$30.43	−$101K	144,994
2025-01-21	APLSApellis Pharmaceuticals, Inc.A Award	General Counsel	AAward	+42.8K sh	—	—	148,317
2025-01-17	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−2,201 sh	$29.96	−$65.9K	105,555
2025-01-13	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−4,965 sh	$28.70	−$143K	107,756
2024-12-11	APLSApellis Pharmaceuticals, Inc.S Sale	General Counsel	SSale	−5,000 sh	$34.23	−$171K	112,721
2024-09-27	APLSApellis Pharmaceuticals, Inc.G Gift	General Counsel	GGift	−10.6K sh	—	—	70,136
2024-09-27	APLSApellis Pharmaceuticals, Inc.G Gift	General Counsel	GGift	+10.6K sh	—	—	117,721
2024-03-06	APLSApellis Pharmaceuticals, Inc.M Exercise/Conversion	General Counsel	MExercise/Conversion	+3,762 sh	$13.85	+$52.1K	107,152

Recent filings

Accepted (ET)
May 144
Watson David O.0001193125-26-224583
SEC(opens sec.gov)

Companies

Apellis Pharmaceuticals, Inc.General CounselAPLS

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451